NASDAQ : CLRB
Cellectar Biosciences, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.22 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 11.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 10.28M | 11.48M | 25.64M | 11.69M | 10.55M | 6.54M |
| Research & Development | 13.25M | 11.50M | 26.14M | 27.27M | 18.27M | 17.59M |
| Operating Expenses | 23.53M | 22.98M | 51.78M | 38.96M | 28.81M | 24.13M |
| Operating Income | -23.53M | -22.98M | -51.78M | -38.96M | -28.81M | -24.13M |
| Interest & Investment Income | 406.47K | 435.10K | 1.21M | 387.15K | 152.52K | 2.28K |
| Other Non Operating Income (Expenses) | 801.11K | 753.71K | 6.05M | -4.26M | -3.19M | 6.63K |
| EBT Excluding Unusual Items | -22.32M | -21.79M | -44.52M | -42.83M | -31.85M | -24.12M |
| Pretax Income | -22.32M | -21.79M | -44.52M | -42.83M | -31.85M | -24.12M |
| Income Tax Expense | 66.00K | -60.00K | -60.00K | |||
| Net Income | -22.32M | -21.79M | -44.58M | -42.77M | -31.79M | -24.12M |
| Net Income to Common | -22.32M | -21.79M | -44.58M | -42.77M | -31.79M | -24.12M |
| Shares Outstanding (Basic) | 5.95M | 2.61M | 1.22M | 407.38K | 235.19K | 185.05K |
| Shares Outstanding (Diluted) | 5.95M | 2.61M | 1.24M | 407.38K | 235.19K | 185.05K |
| EPS (Basic) | -3.75 | -8.35 | -36.52 | -104.99 | -135.18 | -130.35 |
| EPS (Diluted) | -3.75 | -8.35 | -41.89 | -105.00 | -135.18 | -130.35 |
| Free Cash Flow | -19.48M | -23.12M | -47.69M | -33.24M | -25.45M | -22.71M |
| Free Cash Flow Per Share | -3.27 | -8.87 | -38.52 | -81.60 | -108.20 | -122.72 |
| EBITDA | -23.36M | -22.77M | -51.49M | -38.77M | -28.67M | -23.98M |
| D&A For EBITDA | 172.79K | 213.60K | 291.65K | 192.38K | 148.44K | 149.91K |
| EBIT | -23.53M | -22.98M | -51.78M | -38.96M | -28.81M | -24.13M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 33.99M | 13.20M | 23.29M | 9.56M | 19.87M | 35.70M |
| Cash & Short-Term Investments | 33.99M | 13.20M | 23.29M | 9.56M | 19.87M | 35.70M |
| Prepaid Expenses | 883.66K | 842.43K | 961.66K | 888.23K | 663.24K | 867.49K |
| Total Current Assets | 34.88M | 14.04M | 24.25M | 10.45M | 20.53M | 36.57M |
| Property, Plant & Equipment | 1.74M | 910.08K | 1.19M | 1.59M | 978.98K | 549.13K |
| Other Long-Term Assets | 23.57K | 29.78K | 29.78K | 29.78K | 81.21K | 81.21K |
| Total Assets | 36.64M | 14.98M | 25.47M | 12.08M | 21.59M | 37.20M |
| Accounts Payable | 5.22M | 1.44M | 4.11M | 9.18M | 2.56M | 1.41M |
| Accrued Expenses | 2.48M | 2.17M | 2.91M | 2.44M | ||
| Current Portion of Leases | 2.03K | 100.19K | 84.42K | 58.98K | 50.85K | 135.45K |
| Other Current Liabilities | 17.00K | 725.00K | 3.03M | 16.12M | 5.98M | |
| Total Current Liabilities | 5.24M | 4.75M | 9.39M | 25.36M | 11.50M | 3.99M |
| Long-Term Leases | 1.53M | 309.40K | 409.59K | 494.00K | 552.98K | 166.29K |
| Total Liabilities | 6.77M | 5.06M | 9.80M | 25.85M | 12.05M | 4.16M |
| Common Stock | 83.00 | 42.00 | 15.00 | 207.00 | 94.00 | 61.00 |
| Additional Paid-In Capital | 311.59M | 277.15M | 261.12M | 182.92M | 168.14M | 182.56M |
| Retained Earnings | -281.72M | -269.13M | -247.34M | -202.76M | -159.99M | -150.90M |
| Total Common Equity | 29.87M | 8.02M | 13.77M | -19.84M | 8.15M | 31.66M |
| Shareholders' Equity | 29.87M | 9.92M | 15.68M | -13.78M | 9.54M | 33.05M |
| Total Liabilities & Equity | 36.64M | 14.98M | 25.47M | 12.08M | 21.59M | 37.20M |
| Total Debt | 1.53M | 409.59K | 494.00K | 552.98K | 603.83K | 301.74K |
| Net Cash (Debt) | 32.46M | 12.79M | 22.79M | 9.01M | 19.26M | 35.40M |
| Net Cash Per Share | 5.45 | 4.90 | 18.41 | 22.12 | 81.90 | 191.31 |
| Filing Date Shares Outstanding | 9.45M | 4.24M | 1.54M | 1.08M | 324.68K | 203.67K |
| Total Common Shares Outstanding | 8.25M | 4.24M | 1.54M | 691.47K | 312.84K | 203.67K |
| Working Capital | 29.64M | 9.29M | 14.86M | -14.91M | 9.03M | 32.58M |
| Book Value Per Share | 3.62 | 1.89 | 8.97 | -28.69 | 26.06 | 155.46 |
| Tangible Book Value | 29.87M | 8.02M | 13.77M | -19.84M | 8.15M | 31.66M |
| Tangible Book Value Per Share | 3.62 | 1.89 | 8.97 | -28.69 | 26.06 | 155.46 |
| Machinery | 797.28K | 575.37K | ||||
| Leasehold Improvements | 309.90K | 309.90K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -22.32M | -21.79M | -44.58M | -42.77M | -31.79M | -24.12M |
| Depreciation & Amortization | 27.24K | 213.60K | 291.65K | 192.38K | 148.44K | 149.91K |
| Loss (Gain) From Sale of Assets | 145.73K | 3.39K | 2.94K | |||
| Stock-Based Compensation | 2.02M | 2.26M | 4.27M | 2.41M | 1.45M | 1.12M |
| Other Operating Activities | -715.33K | -677.50K | -5.99M | 4.32M | 3.28M | 77.72K |
| Change in Accounts Payable | 539.97K | -3.16M | -1.59M | 3.70M | 1.62M | 411.72K |
| Change in Other Net Operating Assets | 981.06K | 34.82K | -132.42K | -224.39K | 60.21K | -212.96K |
| Operating Cash Flow | -19.47M | -23.12M | -47.58M | -32.38M | -25.22M | -22.57M |
| Capital Expenditures | -9.26K | -5.88K | -104.19K | -864.04K | -225.97K | -141.36K |
| Investing Cash Flow | -9.26K | -5.88K | -104.19K | -864.04K | -225.97K | -141.36K |
| Issuance of Common Stock | 42.44M | 13.03M | 61.41M | 22.94M | 9.61M | 1.25M |
| Financing Cash Flow | 42.44M | 13.03M | 61.41M | 22.94M | 9.61M | 1.25M |
| Net Cash Flow | 22.95M | -10.09M | 13.72M | -10.30M | -15.84M | -21.46M |
| Free Cash Flow | -19.48M | -23.12M | -47.69M | -33.24M | -25.45M | -22.71M |
| Free Cash Flow Per Share | -3.27 | -8.87 | -38.52 | -81.60 | -108.20 | -122.72 |
| Levered Free Cash Flow | -12.52M | -16.43M | -43.97M | -8.99M | -8.83M | -13.63M |
| Unlevered Free Cash Flow | -12.52M | -16.43M | -43.97M | -8.99M | -8.83M | -13.63M |
| Change in Working Capital | 1.52M | -3.13M | -1.73M | 3.48M | 1.68M | 198.76K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 11.53M | 12.51M | 12.34M | 34.04M | 16.05M | 40.57M |
| Enterprise Value | -20.93M | 2.29M | -6.41M | 34.92M | -152.52K | 1.94M |
| Last Close Price | 1.21 | 2.95 | 8.97 | 83.10 | 51.30 | 199.20 |
| PB Ratio | 0.33 | 1.26 | 0.79 | -2.47 | 1.68 | 1.23 |
| P/TBV Ratio | 0.38 | 1.56 | 0.90 | 1.97 | 1.28 | |
| Debt / Equity Ratio | 0.05 | 0.04 | 0.03 | -0.04 | 0.06 | 0.01 |
| Net Debt / Equity Ratio | -1.09 | -1.29 | -1.45 | 0.65 | -2.02 | -1.07 |
| Net Debt / EBITDA Ratio | 1.39 | 0.56 | 0.44 | 0.23 | 0.67 | 1.48 |
| Net Debt / FCF Ratio | 1.67 | 0.55 | 0.48 | 0.27 | 0.76 | 1.56 |
| Quick Ratio | 6.49 | 2.78 | 2.48 | 0.38 | 1.73 | 8.95 |
| Current Ratio | 6.66 | 2.96 | 2.58 | 0.41 | 1.78 | 9.16 |
| Return on Equity (ROE) | -119.57% | -170.27% | -4,693.38% | -149.33% | -54.92% | |
| Return on Assets (ROA) | -58.44% | -71.01% | -172.36% | -144.66% | -61.26% | -31.47% |
| Return on Capital Employed (ROCE) | -74.90% | -224.70% | -321.90% | 293.30% | -285.60% | -72.70% |
| Earnings Yield | -307.48% | -174.21% | -361.29% | -125.65% | -198.10% | -59.46% |
| FCF Yield | -171.07% | -184.87% | -386.45% | -97.66% | -158.57% | -55.98% |
| Buyback Yield / Dilution | -306.49% | -110.67% | -203.92% | -73.22% | -27.09% | -180.20% |